Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enmetazobactam→

Enmetazobactam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1001404-83-6
Molecular formula
C11H14N4O5S
Molecular weight
314.32 g/mol
Drug class
Beta-lactamase inhibitorcomponent of cefepime/enmetazobactam antibacterial combination
Mechanism of action
Inhibits class A beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), protecting cefepime from hydrolysis and restoring antibacterial activity against susceptible Gram-negative organisms.
Indications / reported uses
  • Component of the fixed combination cefepime/enmetazobactam (EXBLIFEP) for adults with complicated urinary-tract infections, including pyelonephritis, caused by susceptible Gram-negative bacteria; not a standalone antibiotic indication

Sources: US DailyMed — EXBLIFEP (cefepime/enmetazobactam) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enmetazobactam Environmental Risk Assessment (ERA) (the Enmetazobactam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.